HighVista Strategies LLC Buys 6,018 Shares of Pharvaris (NASDAQ:PHVS)

HighVista Strategies LLC grew its stake in shares of Pharvaris (NASDAQ:PHVS) by 35.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,768 shares of the company’s stock after acquiring an additional 6,018 shares during the period. HighVista Strategies LLC’s holdings in Pharvaris were worth $422,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of PHVS. Novo Holdings A S raised its stake in Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after buying an additional 556,970 shares in the last quarter. Sofinnova Investments Inc. raised its position in shares of Pharvaris by 2.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock worth $11,309,000 after acquiring an additional 16,862 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after purchasing an additional 335,687 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Pharvaris during the third quarter valued at about $906,000.

Wall Street Analyst Weigh In

Separately, Oppenheimer boosted their target price on shares of Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Pharvaris has an average rating of “Moderate Buy” and an average target price of $33.60.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $19.78 on Wednesday. Pharvaris has a fifty-two week low of $15.37 and a fifty-two week high of $33.00. The company’s 50-day simple moving average is $21.07 and its 200-day simple moving average is $19.29.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.